Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML)
Eric Padron(Moffitt Cancer Center), Pearlie K. Epling‐Burnette(AbbVie (United States)), Jeffrey E. Lancet(Cornell University), Kathy L. McGraw(National Institutes of Health), Alan F. List(TE Laboratories (Ireland)), Jeffrey S. Painter(University of South Florida), Jessica M. McDaniel(University of South Florida), Mark Baer, Geoffrey Yarranton, Adam W. Mailloux(University of South Florida), Christopher Bebbington(Curtin University), Rami S. Komrokji(Moffitt Cancer Center)
Cited by 1
Related Papers
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
|Journal of Clinical Oncology|2018|983
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
|Journal of Clinical Oncology|2009|963
Efficacy of Lenalidomide in Myelodysplastic Syndromes
|New England Journal of Medicine|2005|874
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
|Nature Genetics|2020|739